Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 59% Improvement Relative Risk Lagier et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 3,737 patients in France Lower mortality with HCQ (p=0.048) Lagier et al., Travel Med. Infect. Dis. 101791, .., doi:10.1016/j.tmaid.2020.101791 Favors HCQ Favors control
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
Lagier et al., Travel Med. Infect. Dis. 101791, Jun 25, 2020, doi:10.1016/j.tmaid.2020.101791
Lagier et al., Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in.., Travel Med. Infect. Dis. 101791, Jun 25, 2020, doi:10.1016/j.tmaid.2020.101791
Jun 2020   Source   PDF  
  All Studies   Meta
Early treatment leads to significantly better clinical outcome and faster viral load reduction. Matched sample mortality HR 0.41 p-value 0.048. Retrospective 3,737 patients. This study includes both outpatients and hospitalized patients.
risk of death, 59.0% lower, HR 0.41, p = 0.048, treatment 35 of 3,119 (1.1%), control 58 of 618 (9.4%), adjusted per study.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lagier et al., 25 Jun 2020, retrospective, France, peer-reviewed, 22 authors, dosage 200mg tid days 1-10.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: Travel Medicine and Infectious Disease 36 (2020) 101791 Contents lists available at ScienceDirect Travel Medicine and Infectious Disease journal homepage: Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/ azithromycin and other regimens in Marseille, France: A retrospective analysis Jean-Christophe Lagier a, b, 1, Matthieu Million a, b, 1, Philippe Gautret a, c, Philippe Colson a, b, S�ebastien Cortaredona a, c, Audrey Giraud-Gatineau a, c, d, e, St�ephane Honor�e f, g, Jean-Yves Gaubert h, Pierre-Edouard Fournier a, c, Herv�e Tissot-Dupont a, b, Eric Chabri�ere a, b, Andreas Stein a, b, Jean-Claude Deharo i, Florence Fenollar a, c, Jean-Marc Rolain a, b, Yolande Obadia a, Alexis Jacquier j, Bernard La Scola a, b, Philippe Brouqui a, b, Michel Drancourt a, b, Philippe Parola a, c, Didier Raoult a, b, *, IHU COVID-19 Task force a IHU-M�editerran�ee Infection, Marseille, France Aix Marseille University, IRD, AP-HM, MEPHI, Marseille, France Aix Marseille University, IRD, AP-HM, SSA, VITROME, Marseille, France d Centre d’Epid�emiologie et de Sant�e Publique des Arm�ees (CESPA), Marseille, France e AP-HM, Marseille, France f Aix Marseille University, Laboratoire de Pharmacie Clinique, Marseille, France g AP-HM, H^ opital Timone, Service Pharmacie, Marseille, France h Department of Radiology and Cardiovascular Imaging, Aix Marseille Univ, LIIE, Marseille, France i AP-HM, Aix Marseille University, H^ opital Timone, Cardiologie, Rythmologie, Marseille, France j Department of Radiology and Cardiovascular Imaging, Aix-Marseille Univ., UMR 7339, CNRS, CRMBM-CEMEREM (Centre de R�esonance Magn�etique Biologique et M�edicale-Centre d’Exploration M�etaboliques Par R�esonance Magn�etique), Marseille, France b c A R T I C L E I N F O A B S T R A C T Keywords: SARS-CoV-2 COVID-19 Hydroxychloroquine Azithromycin Background: In our institute in Marseille, France, we initiated early and massive screening for coronavirus disease 2019 (COVID-19). Hospitalization and early treatment with hydroxychloroquine and azithromycin (HCQ-AZ) was proposed for the positive cases. Methods: We retrospectively report the clinical management of 3,737 screened patients, including 3,119 (83.5%) treated with HCQ-AZ (200 mg of oral HCQ, three times daily for ten days and 500 mg of oral AZ on day 1 fol­ lowed by 250 mg daily for the next four days, respectively) for at least three days and 618 (16.5%) patients treated with other regimen (“others”). Outcomes were death, transfer to the intensive care unit (ICU), �10 days of hospitalization and viral shedding. Results: The patients’ mean age was 45 (sd 17) years, 45% were male, and the case fatality rate was 0.9%. We performed 2,065 low-dose computed tomography (CT) scans highlighting lung lesions in 592 of the 991 (59.7%) patients with minimal clinical symptoms (NEWS score ¼ 0). A discrepancy between spontaneous dyspnoea, hypoxemia and lung lesions was observed. Clinical factors (age, comorbidities, NEWS-2 score), biological factors (lymphocytopenia; eosinopenia; decrease in blood zinc; and increase in D-dimers, lactate dehydrogenase, creatinine phosphokinase, troponin and C-reactive protein) and moderate and severe lesions detected in low-dose CT scans were associated with poor clinical outcome. Treatment with HCQ-AZ was associated with a decreased risk of transfer to ICU or death (Hazard ratio (HR) 0.18 0.11–0.27), decreased risk of hospitalization �10 days (odds ratios 95%..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop